Home » Topics » Neurology/psychiatric, BioWorld Science

Neurology/psychiatric, BioWorld Science
RSS

Side effects of botulinum toxin A in the treatment of craniocervical dystonias

Sep. 13, 1996

Rhodanines for multiple sclerosis

Sep. 13, 1996

New treatment strategy for Parkinson's disease introduced

Sep. 13, 1996

New formulation of selegiline

Sep. 13, 1996

Dopaminergic agents claimed by Sandoz

Sep. 13, 1996

A major breakthrough in the treatment of schizophrenia

Sep. 13, 1996

New compounds from Roche with affinity for benzodiazepine receptors

Sep. 13, 1996

Merck & Co. synthesizes dopamine D4 receptor ligands

Sep. 13, 1996

Divestment of antimigraine treatment from Glaxo Wellcome to Zeneca

Sep. 13, 1996

Controlled-release oral analgesic formulation claimed by Euroceltique

Sep. 13, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 16, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...